We then introduced ESC-derived EPCs into the circulation of hyperoxia-injured BPD mice and demonstrated that cellular therapy with in vitro differentiated c-KIT+FOXF1+ EPCs can increase neonatal lung angiogenesis and decrease alveolar simplification in a murine model of BPD. Here, FOXF1 is linked to bronchopulmonary dysplasia.